HXN-1011 / Earendil Labs - LARVOL DELTA

AI-Guided Design and Development of HXN-1011: A Potent Anti-TSLP Biparatopic Antibody (EADV 2025) - "Furthermore, in an OVA-induced asthma model using hTSLP/hTSLPR transgenic mice, HXN- 1011 effectively reduced lung inflammation, as evidenced by decreased BALF cell counts, eosinophil levels, and CCL17 expression, outperforming both Tezepelumab and GSK5784283. Furthermore, in an MC903+OVA-induced skin and lung inflammation model, HXN-1011 demonstrated superior efficacy across all tested parameters including reductions in epidermal hyperplasia, immune cell infiltration and lung inflammation... HXN-1011 is a next-generation biparatopic antibody exhibiting exceptional potency and holding significant potential to enhance clinical efficacy in the treatment of TSLP-driven inflammatory diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other related indications. Preclinical studies and IND-enabling research for HXN-1011 are currently underway."

Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Dermatitis • Dermatology • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • CRLF2 • IL7R • STAT5 • STAT5AWqe • TSLP

AI-Guided Design and Development of HXN-1011: A Potent Anti-TSLP Biparatopic Antibody (EAACI 2025) - "Results Epitope mapping confirmed that HXN-1011 simultaneously binds to both Site I and Site II, while other TSLP antibodies, including Tezepelumab (AstraZeneca), GSK5784283 (GSK/Hengrui), and CM326 (Keymed), bind only to Site I. HXN-1011 exhibited a binding affinity approximately 100-fold higher than Tezepelumab and achieved IC90 values 15- to 100-fold lower in functional assays...HXN-1011 also showed superior efficacy across all tested parameters in OVA+MC903-induced lung and skin inflammation...Conclusion HXN-1011 is a next-generation biparatopic antibody with exceptional potency and significant potential to improve clinical efficacy in treating TSLP-driven inflammatory diseases, such as asthma, COPD, and beyond. Preclinical studies and IND-enabling research for HXN-1011 are currently in progress."

Late-breaking abstract • Dermatitis • Immunology • Inflammation • CRLF2 • IL7R • STAT5 • STAT5AWqe • TSLP

AI-guided Generation and Development of HXN-1011, A Highly Potent Anti-TSLP Biparatopic Antibody (ATS 2025) - " Epitope mapping confirmed that HXN-1011 simultaneously binds to both Site I and Site II, while other TSLP antibodies, including Tezepelumab (AstraZeneca), GSK5784283 (GSK/Hengrui), and CM326 (Keymed), bind only to Site I. HXN-1011's binding affinity is ∼100 times higher than that of Tezepelumab. HXN-1011 is a highly potent biparatopic antibody targeting TSLP. It has great potential to significantly enhance clinical efficacy and expand to other inflammatory diseases beyond asthma/COPD. Preclinical and IND-enabling studies of HXN-1011 are currently underway."

Asthma • Chronic Obstructive Pulmonary Disease • Inflammation • Pneumonia • Respiratory Diseases • CRLF2 • IL7R • STAT5 • STAT5AWqe • TSLP